PRESS-RELEASE ·Filed Jun 15, 2026
Press release · Announcement
Actionable Insight • Neutral
This filing is a routine equity inducement grant with no impact on company fundamentals. Traders should focus on upcoming commercial milestones for PEDMARK/PEDMARQSI, including revenue growth and market expansion updates.
Final — all horizons settled through T+60d
FENC ▲ +26.77% at T+60d
NEUTRAL call +26.77% · α vs SPY +25.77% · entry $9.19 → $11.65
T+1d
-2.50%
call -2.50% · α -1.91%
$8.96
settled 4mo ago
T+5d
+3.70%
call +3.70% · α +5.08%
$9.53
settled 4mo ago
T+20d
+16.98%
call +16.98% · α +17.72%
$10.75
settled 3mo ago
T+60d
+26.77%
call +26.77% · α +25.77%
$11.65
settled 7w ago
Price Chart
Loading chart...
Executive Summary
Fennec Pharmaceuticals granted 10,000 incentive stock options to a new non-executive employee at $9.00 per share under its 2024 Equity Inducement Plan. This is a routine inducement grant with no material financial or operational impact.
Key Facts
- Grant of 10,000 incentive stock options to one new non-executive employee
- Exercise price of $9.00 per share, equal to June 12, 2026 closing price
- Options vest one-third on one-year anniversary, then monthly over 24 months
- Granted under Nasdaq Listing Rule 5635(c)(4) as inducement material to employment
Financial Impact
Minimal; 10,000 shares represent less than 0.1% of outstanding shares
dilution
Risk Factors
- No material risks from this filing; company's commercial execution remains key risk
Market Snapshot
Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (13 analysts)
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3311609 |
18 reports for FENC
100% Hit rate @ T+60 Went positive at some point 4 of 5 best @ T+60▲ +50.50%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | SC 13G/A | $10.27 | awaiting T+60 | — | $10.60 (+3.16%) |
Aug 31, 2026 8w ago | Insider Cluster | $12.03 | awaiting T+60 | — | $10.60 (−11.93%) |
Aug 31, 2026 8w ago | Insider Cluster | $12.03 | awaiting T+60 | — | $10.60 (−11.93%) |
Aug 11, 2026 11w ago | Press Release | $12.78 | awaiting T+60 | — | $10.60 (−17.10%) |
Jun 15, 2026 19w ago | Press Release | $9.19 $11.65 | ▲ +26.77% | ▲ +25.77% | $10.60 (+15.29%) |
May 22, 2026 22w ago | 8-K | $9.89 $11.87 | ▲ +20.02% | ▲ +17.30% | $10.60 (+7.13%) |
May 18, 2026 23w ago | 8-K | $9.76 $12.06 | ▲ +23.57% | ▲ +17.28% | $10.60 (+8.56%) |
May 14, 2026 23w ago | Press Release | $9.24 $10.94 | ▲ +18.40% | ▲ +14.81% | $10.60 (+14.66%) |
May 7, 2026 24w ago | Press Release | $6.90 $9.59 | ▲ +38.99% | ▲ +35.15% | $10.60 (+53.55%) |
Apr 28, 2026 25w ago | 8-K | $6.26 $9.99 | ▲ +59.58% | ▲ +55.47% | $10.60 (+69.25%) |
Showing 10 of 18
US Market Status
Market Open — Closes in 43m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers